Cargando…

Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease

AIMS/INTRODUCTION: Non‐alcoholic fatty liver disease is frequently associated with type 2 diabetes, and constitutes an important risk factor for the development of hepatic fibrosis and hepatocellular carcinoma. Because there remains no effective drug therapy for non‐alcoholic fatty liver disease ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Mitsuko, Hayashi, Akinori, Taguchi, Tomomi, Arai, Riina, Sasaki, Sayaka, Takano, Koji, Inoue, Yusuke, Shichiri, Masayoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626966/ https://www.ncbi.nlm.nih.gov/pubmed/30461221 http://dx.doi.org/10.1111/jdi.12980

Ejemplares similares

Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease
por: Nishimiya, Noriko, et al.
Publicado: (2021)

A Case With Adult GH Deficiency Complicated With Osteogenesis Imperfecta: Effect of GH Replacement on Bone Mineral Density
por: Taguchi, Tomomi, et al.
Publicado: (2021)

Short-term Change in Resting Energy Expenditure and Body Compositions in Therapeutic Process for Graves' Disease
por: Hayashi, Akinori, et al.
Publicado: (2020)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017)

Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: historical cohort study
por: Chida, Shoma, et al.
Publicado: (2016)

Suprabasin-derived bioactive peptides identified by plasma peptidomics
por: Taguchi, Tomomi, et al.
Publicado: (2021)

Identification and quantification of plasma free salusin-β, an endogenous parasympathomimetic peptide
por: Fujimoto, Kazumi, et al.
Publicado: (2017)

ANGT_HUMAN[448–462], an Anorexigenic Peptide Identified Using Plasma Peptidomics
por: Sasaki, Sayaka, et al.
Publicado: (2022)

ATP6AP2 is robustly expressed in pancreatic β cells and neuroendocrine tumors, and plays a role in maintaining cellular viability
por: Taguchi, Tomomi, et al.
Publicado: (2023)

New Indices for Predicting Glycaemic Variability
por: Ogawa, Akifumi, et al.
Publicado: (2012)

Oxidised Met(147) of human serum albumin is a biomarker of oxidative stress, reflecting glycaemic fluctuations and hypoglycaemia in diabetes
por: Momozono, Akari, et al.
Publicado: (2020)

Effects of canagliflozin on weight loss in high-fat diet-induced obese mice
por: Ji, Wenjun, et al.
Publicado: (2017)

Robust increase in glucagon secretion after oral protein intake, but not after glucose or lipid intake in Japanese people without diabetes
por: Ichikawa, Raishi, et al.
Publicado: (2023)

Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
por: Orešič, Matej, et al.
Publicado: (2013)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2021)

Improved AcroQoL scores in acromegaly after sagittal split ramus osteotomy with Le Fort I osteotomy
por: Taguchi, Tomomi, et al.
Publicado: (2021)

Methionine sulfoxides in serum proteins as potential clinical biomarkers of oxidative stress
por: Suzuki, Satoko, et al.
Publicado: (2016)

Correction: Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2023)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice
por: Ohashi, Tomohiko, et al.
Publicado: (2019)

Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
por: Itani, Toshio, et al.
Publicado: (2018)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Characterization of Retail Conventional, Organic, and Grass Full-Fat Butters by Their Fat Contents, Free Fatty Acid Contents, and Triglyceride and Fatty Acid Profiling
por: Pustjens, Annemieke M., et al.
Publicado: (2017)

Patient profiling in diabetes and role of canagliflozin
por: Amblee, Ambika
Publicado: (2014)

Prolonged diabetic ketoacidosis associated with canagliflozin
por: Sloan, Gordon, et al.
Publicado: (2018)

Repurposing Canagliflozin to target brain aging
por: Jayarathne, Hashan, et al.
Publicado: (2023)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Fat content, fatty acid pattern and iron content in livers of turkeys with hepatic lipidosis
por: Visscher, Christian, et al.
Publicado: (2017)

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
por: Borisov, Angel N, et al.
Publicado: (2023)

THE RELATION BETWEEN THE FAT CONTENT OF THE BILE AND FATTY CHANGES IN THE LIVER
por: Le Count, Edwin R., et al.
Publicado: (1914)

Spleen-Derived Interleukin-10 Downregulates the Severity of High-Fat Diet-Induced Non-Alcoholic Fatty Pancreas Disease
por: Gotoh, Koro, et al.
Publicado: (2012)

LPIAT1 regulates arachidonic acid content in phosphatidylinositol and is required for cortical lamination in mice
por: Lee, Hyeon-Cheol, et al.
Publicado: (2012)

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
por: Xu, Zhipeng, et al.
Publicado: (2022)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki, Satoko, et al.
Publicado: (2020)

Circulating Levels of Human salusin-β,a Potent Hemodynamic and Atherogenesis Regulator
por: Fujimoto, Kazumi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cp64dts5rcrgj9uclmomcb201g